Phase 4 N=41 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
Turner Syndrome · Hypogonadism · Premature Ovarian Failure
Primary: Change in Weight From Baseline at 12 Months — 1.1; 1.9 kilograms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Estradiol Levels in Patients Treated With Estring
Estrogen Levels Among Breast Cancer Patients
Primary: Changes in Serum Estradiol — 3.9 pg/mL
Phase 2 N=23 Effect of Race on Gonadotropin Responses
Premenopause · Healthy
Primary: LH Peak in Response to Estrogen Positive Feedback — 80.3; 73.1 IU/L — p=0.69
Phase 1 N=30 Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Healthy
Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
N/A N=31 Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
Atrophic Vaginitis · Breast Cancer
Primary: Change in Serum Estradiol From Baseline to Week 12 — 5.21; 4.46; 5.23; 6.72 pg/ml
Phase 2 N=25 Postmenopausal Women Estrogen and Progesterone Infusion
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Phase 2 N=46 Estrogen Receptor Beta and Mood
Perimenopause-Related Depression
Primary: Center for Epidemiologic Studies-Depression (CES-D) Scale Mean Total Score — 12.96; 18.02; 11.53; 9.43 Units on a scale
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
Phase 2 N=72 Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
Phase 3 N=315 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
HER2-Positive Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma · Stage IB Breast Cancer AJCC v7
Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants
N/A N=17 Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
Cognitive Impairment · Executive Dysfunction · Endothelial Dysfunction
Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight
Phase 2 N=30 Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Estrogen Receptor Negative · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Number of Participants With Overall Response — 5; 2 Participants
Phase 2 N=118 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Metastatic Breast Carcinoma · Stage IIIB Breast Cancer AJCC v7 · Stage IIIC Breast Cancer AJCC v7
Primary: Number of Participants With Progression Free Survival (PFS) at 12 Months — 8; 16 Participants
N/A N=47 The Effects of Menstrual Cycle Phase on Exercise Treadmill Test Results in Premenopausal Women
Menstrual Cycle · Exercise Treadmill
Primary: ST/HR Index (μV/Bpm) — 1.2; 1.3 μV/Bpm — p=0.521